Evidence map›Paper›PMID 26907630›Full record

ArticleBlood2016

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla-Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C Jensen, Stanley R Riddell, David G Maloney and 1 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 476 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
476citing papers in PubMed, 2 pooled it
37.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

476 citing papers in PubMed, 2 syntheses or guidelines pooled it, 738 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026
    Review
  20. Article

416 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Rebecca GardnerSeattle Children's Research Institute, Department of Pediatrics, and.
David WuDepartment of Laboratory Medicine, University of Washington, Seattle, WA;
Sindhu CherianDepartment of Laboratory Medicine, University of Washington, Seattle, WA;
Min FangDepartment of Laboratory Medicine, University of Washington, Seattle, WA;
Laïla-Aïcha HanafiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
Olivia FinneySeattle Children's Research Institute.
Hannah SmithersSeattle Children's Research Institute.
Michael C JensenSeattle Children's Research Institute, Department of Pediatrics, and.
Stanley R RiddellClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Department of Medicine, University of Washington, Seattle, WA.
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Department of Medicine, University of Washington, Seattle, WA.
Cameron J TurtleClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Department of Medicine, University of Washington, Seattle, WA.
University of Washington · USFred Hutch Cancer Center · USPediatrics and Genetics · US

Funding

Targeted therapy of B cell malignances with CAR-T cells of defined compositionR01CA136551 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JENSEN, MICHAEL C, RIDDELL, STANLEY R. · 2009 to 2018
$5.5M
NCI NIH HHS R01 CA136551
6 · The paper itself

Abstract

Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a remarkably effective approach to treating patients with relapsed and refractory CD19(+) B-cell malignancies. We treated 7 patients with B-cell acute lymphoblastic leukemia (B-ALL) harboring rearrangement of the mixed lineage leukemia (MLL) gene with CD19 CAR-T cells. All patients achieved complete remission (CR) in the bone marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cell infusion, 2 of the patients developed acute myeloid leukemia (AML) that was clonally related to their B-ALL, a novel mechanism of CD19-negative immune escape. These reports have implications for the management of patients with relapsed and refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.

Indexed as

Immunotherapy, AdoptiveTumor EscapeAntigens, CD19Antineoplastic Combined Chemotherapy ProtocolsBone MarrowChromosomes, Human, Pair 11Clone CellsCombined Modality TherapyFemaleHistone-Lysine N-MethyltransferaseHumansImmunophenotypingInfantLeukemia, Myeloid, AcuteLymphocyte DepletionMiddle AgedAntigens, CD19CD19 molecule, humanCD19-specific chimeric antigen receptorHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionReceptors, Antigen, T-Cell

Identifiers

PMID26907630
PMCPMC4874221
OpenAlexW2400439118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.